GR1000250B - Πυκτωματικες συνθεσεις που περιεχουν παραγοντες αναπτυξης. - Google Patents

Πυκτωματικες συνθεσεις που περιεχουν παραγοντες αναπτυξης.

Info

Publication number
GR1000250B
GR1000250B GR880100617A GR880100617A GR1000250B GR 1000250 B GR1000250 B GR 1000250B GR 880100617 A GR880100617 A GR 880100617A GR 880100617 A GR880100617 A GR 880100617A GR 1000250 B GR1000250 B GR 1000250B
Authority
GR
Greece
Prior art keywords
condensation
coagulation
peak
formations
eye
Prior art date
Application number
GR880100617A
Other languages
English (en)
Other versions
GR880100617A (en
Inventor
Rao S Bezwada
M Jonathan Cohen
L Amy Finkenaur
Richard L Kronenthal
A Elisabeth Sandoval
W Shalaby Shalaby
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon Inc filed Critical Ethicon Inc
Publication of GR880100617A publication Critical patent/GR880100617A/el
Publication of GR1000250B publication Critical patent/GR1000250B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Παρέχονται μορφοποιήσεις πηκτής που περιέχουν πολυπεπτιδικούς παράγοντες ανάπτυξης έχοντας ανθρώπινη μιτογενεσιακή και αγγειογενεσιακή δράση. Οι μορφοποιήσεις πηκτής είναι χρήσιμες για τη θεραπεία πληγών επεδερμικών τραυμάτων τοπικών ή τομής (χειρουργικής), για τον πρόσθιο θάλαμο του οφθαλμού και άλλα οφθαλμικά τραύματα. Οι μορφοποιήσεις πηκτής περιλαμβάνουν επίσης ένα ευδιάλυτο σε νερό, φαρμακευτικά ή οφθαλμικά συμβατό πολυμερικό υλικό, προς παροχή ιξώδους εντός διαφορετικών πεδίων τιμών που προσδιορίζεται από τις ανάγκες της τοποθέτησης της πηκτής. Οι μορφοποιήσεις πηκτής παρέχουν ελεγχόμενη έκλυση του παράγοντα ανάπτυξης στη θέση της πληγής (τραύματος). ω
GR880100617A 1987-09-18 1988-09-16 Πυκτωματικες συνθεσεις που περιεχουν παραγοντες αναπτυξης. GR1000250B (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9881687A 1987-09-18 1987-09-18
US23348388A 1988-08-19 1988-08-19

Publications (2)

Publication Number Publication Date
GR880100617A GR880100617A (en) 1989-06-22
GR1000250B true GR1000250B (el) 1992-05-12

Family

ID=26795141

Family Applications (1)

Application Number Title Priority Date Filing Date
GR880100617A GR1000250B (el) 1987-09-18 1988-09-16 Πυκτωματικες συνθεσεις που περιεχουν παραγοντες αναπτυξης.

Country Status (9)

Country Link
US (1) US5427778A (el)
EP (1) EP0312208A1 (el)
JP (1) JPH02112A (el)
KR (1) KR890004720A (el)
AU (1) AU2223588A (el)
GR (1) GR1000250B (el)
MX (1) MX169808B (el)
NZ (1) NZ226171A (el)
PT (1) PT88541A (el)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124316A (en) * 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US4874746A (en) * 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
EP0386960A3 (en) * 1989-03-07 1991-10-23 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5271943A (en) 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
LU87624A1 (fr) * 1989-11-16 1991-07-22 Oreal Composition pharmaceutique et/ou cosmetique contenant un facteur de croissance hypophysaire(hdgf)stabilise par de l'elastine soluble
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
EP0526578A4 (en) * 1990-04-26 1993-09-22 Cytrx Corporation Composition and method for topical treatment of damaged or diseased tissue
ES2178633T3 (es) * 1990-05-30 2003-01-01 Harvard College Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos.
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
GB2248842A (en) * 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
US5955436A (en) * 1990-11-20 1999-09-21 Alcon Laboratories, Inc. Use of platelet derived growth factor to enhance wound healing
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7229959B1 (en) 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
EP0564502B1 (en) * 1990-11-27 2002-01-30 The American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
SE501217C2 (sv) * 1990-12-06 1994-12-12 Skandigen Ab Cellproliferationsmatris och användning därav
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
GB9102107D0 (en) * 1991-01-31 1991-03-13 Erba Carlo Spa Stabilisation of fibroblast growth factor using a polysaccharide
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
GR920100122A (el) * 1991-04-05 1993-03-16 Ethicon Inc Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
EP0510270A1 (en) * 1991-04-25 1992-10-28 LINDSTROM, Richard L. Viscoelastic solution
EP0516026A1 (en) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel and method of producing same
JP3305355B2 (ja) * 1991-06-03 2002-07-22 三菱化学株式会社 肝実質細胞増殖剤
TW318142B (el) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
JPH06500802A (ja) * 1991-06-14 1994-01-27 アムジエン・インコーポレーテツド コラーゲンフィルムによるタンパクのドラッグ・デリバリー
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
FR2678832B1 (fr) * 1991-07-10 1995-03-17 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
DK0608353T3 (da) * 1991-10-16 1996-07-01 Richardson Vicks Inc Vandig, kosmetisk gel med lav pH-værdi og indeholdende ikke-ioniske polyacrylamidderivater
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
ES2114569T3 (es) * 1991-10-16 1998-06-01 Richardson Vicks Inc Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos.
CA2080537A1 (en) * 1991-10-21 1993-04-22 David B. Volkin Stabilized topical acidic fibroblast growth factor formulation
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
DE4209722C3 (de) * 1992-03-25 1997-06-19 Medproject Pharma Entwicklungs Tropfbares Gel für die Augenheilkunde
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
KR950702436A (ko) * 1992-07-28 1995-07-29 자코부스 코르넬리스 라세르 가교 결합 양이온성 중합체 및 알콜실화 에테르를 함유하는 국소용 약학 조성물(pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether)
FR2699545B1 (fr) * 1992-12-18 1995-01-27 Oreal Agent gélifiant résultant de l'association d'un chitosane et d'un alginate d'alkyle ou d'hydroxyalkyle et son utilisation dans la préparation de compositions cosmétiques et pharmaceutiques.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ATE203913T1 (de) * 1993-05-31 2001-08-15 Kaken Pharma Co Ltd Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
US5989536A (en) * 1993-07-03 1999-11-23 The Procter & Gamble Company Personal cleansing compositions containing alkoxylated ether and cationic ammonium salt for deposition of active agent upon the skin
CU22405A1 (es) * 1993-07-05 1996-01-31 Cigb Composicion cosmetica para el cuidado de la piel
JP3952508B2 (ja) * 1993-11-09 2007-08-01 ニューロスフィアーズ ホウルディングス リミテッド 中枢神経系の幹細胞の原位置修飾及び操作
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US20030105007A1 (en) * 1995-06-07 2003-06-05 Andre Beaulieu PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
CA2224253A1 (en) * 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
JPH09143093A (ja) * 1995-11-17 1997-06-03 Hoechst Japan Ltd 軟骨・骨誘導性修復用材料
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
AU2063197A (en) * 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US20110207666A1 (en) * 1996-03-05 2011-08-25 Depuy Spine, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6645945B1 (en) 1996-03-05 2003-11-11 Depuy Acromed, Inc. Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
NZ331238A (en) * 1996-03-05 2000-05-26 Orquest Inc Method of promoting bone growth with hyaluronic acid and growth factors (bFGF)
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
KR100231805B1 (ko) * 1997-01-09 1999-12-01 윤재승 인간상피세포 성장인자를 함유하는 피부외용제 조성물
US6630442B1 (en) * 1997-01-10 2003-10-07 Theodore Hersh Reparatives for chemosurgery and laser (thermal) therapy
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
US6138683A (en) * 1997-09-19 2000-10-31 Thione International, Inc. Smokeless tobacco products containing antioxidants
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
US6491904B1 (en) 1998-03-07 2002-12-10 Daewoong Pharmaceutical Co., Ltd. Topical composition containing human epidermal growth factor
US20030147860A1 (en) 2002-02-07 2003-08-07 Marchosky J. Alexander Compositions and methods for forming and strengthening bone
US6497893B1 (en) 1999-06-30 2002-12-24 Kimberly-Clark Worldwide, Inc. Silk protein treatment composition and treated substrate for transfer to skin
DE69936212T2 (de) * 1998-09-04 2008-01-24 Scios Inc., Sunnyvale Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren
MXPA01003483A (es) 1998-10-05 2002-09-18 Penn State Res Found Composiciones y metodos para mejorar la internalizacion celular mediada por el receptor.
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US6645947B1 (en) 1999-05-20 2003-11-11 Chitogenics, Inc. Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
DE19925519A1 (de) 1999-06-04 2000-12-07 Lohmann Therapie Syst Lts Wundauflage zur gesteuerten Abgabe von Wirkstoff an Wunden und Verfahren zu ihrer Herstellung
AU782394B2 (en) * 1999-06-29 2005-07-21 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
US6506394B1 (en) 1999-06-30 2003-01-14 Kimberly-Clark Worldwide, Inc. Delivery of a botanical extract to a treated substrate for transfer to skin
US6500443B1 (en) * 1999-06-30 2002-12-31 Kimberly-Clark Worldwide, Inc. Delivery of a sacrificial substrate to inhibit protease permeation into skin
US9616150B2 (en) * 1999-10-29 2017-04-11 Children's Hospital Los Angeles Bone hemostasis method and materials
DE19957388A1 (de) 1999-11-24 2001-06-13 Michael Sittinger Chondroinduktive und implantierbare Substrate zur Knorpelheilung und -protektion
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
DE60130872T2 (de) * 2000-03-10 2008-07-17 Insite Vision, Inc., Alameda Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CN1626533A (zh) 2000-04-19 2005-06-15 盐野义制药株式会社 磺酰胺衍生物的制备方法及其晶体
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US6503524B1 (en) 2000-06-16 2003-01-07 Kimberly-Clark Worldwide, Inc. Delivery of a skin health benefit agent to a treated substrate for transfer to skin
TWI305778B (en) 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
EP1476135A1 (en) 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7265097B2 (en) 2002-08-20 2007-09-04 Chitogenics, Inc. Methods of drug delivery using sulphated chitinous polymers
AU2003270401B2 (en) 2002-09-10 2008-03-13 American National Red Cross Hemostatic dressing
JP2006347883A (ja) * 2003-09-08 2006-12-28 Neetec:Kk 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20120283232A9 (en) * 2003-11-12 2012-11-08 Zhengjun Wang Process for making a pharmaceutical composition
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005107723A2 (en) * 2004-05-06 2005-11-17 Rashid Buttar Transdermal delivery systems and transdermal chelation preparations
ITMI20041376A1 (it) * 2004-07-09 2004-10-09 Uni Campus Bio Medico Di Roma Metodo di preparazione di un sistema polimerico biocompatibile per il rilascio farmacologico in uso topico e impieghi di detto sistema
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
EP1787643A1 (en) * 2004-09-09 2007-05-23 Jimenez Bayardo, Arturo Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof
JP5031370B2 (ja) * 2004-09-17 2012-09-19 セルジェンテック株式会社 外用皮膚潰瘍治療剤
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8481049B2 (en) * 2005-05-27 2013-07-09 Bharat Biotech International Limited Methods for treating a wound using epidermal growth factor formulation
AU2006259408A1 (en) * 2005-06-17 2006-12-28 Genentech, Inc. Use of VEGF for wound healing
KR100748390B1 (ko) * 2005-11-14 2007-08-10 주식회사 대웅 상피세포성장인자를 포함하는 상처치료용 서방성 필름 제형
KR100687281B1 (ko) * 2005-11-30 2007-02-27 한국과학기술연구원 생리 활성 물질이 결합된 조직 재생용 주입형 온도 감응성플루로닉 유도체 하이드로겔 및 이의 제조 방법
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
EP2063831A4 (en) 2006-08-04 2010-10-06 Stb Lifesaving Technologies In SOLID FIRM FOR THE TREATMENT OF WOUND FABRICS
CN101522164B (zh) 2006-09-13 2014-03-26 提升肤质产品公司 用于治疗皮肤的化妆品组合物及其方法
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
WO2009020612A1 (en) 2007-08-06 2009-02-12 Stb Lifesaving Technologies, Inc. Methods and dressing for sealing internal injuries
JP5123718B2 (ja) * 2008-04-15 2013-01-23 株式会社ゼロワン 茶殻等リサイクルシステム
IT1394690B1 (it) 2008-10-23 2012-07-13 Carli De Metodo di trattamento dermocosmetico della cute mediante applicazione di composizioni contenenti ngf.
SG181969A1 (en) * 2010-01-06 2012-08-30 Orf Liftaekni Hf Method of use of stabilized plant-derived growth factor in skin care
EP2353624A1 (en) 2010-02-10 2011-08-10 Université de la Méditerranée - Aix-Marseille II Embolic material, its process of preparation and its therapeutical uses thereof
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
EP2758031A1 (en) 2011-09-22 2014-07-30 Bausch & Lomb Incorporated Ophthalmic gel compositions
ES2867054T3 (es) 2011-10-11 2021-10-20 Inst Nat Sante Rech Med Tratamiento de salto de exones para epidermólisis ampollosa distrófica
WO2013079580A1 (en) 2011-11-29 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
CN102512357A (zh) * 2012-01-11 2012-06-27 厦门大学 一种神经生长因子眼用凝胶及其制备方法
MX2015002208A (es) 2012-08-31 2015-05-08 Bausch & Lomb Composiciones oftalmicas con acidos grasos omega-3.
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
JP2016519667A (ja) * 2013-03-15 2016-07-07 シネジェン， インコーポレイテッド 創傷治癒のための組成物および使用方法
MX2017004520A (es) 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.
EP3470059B1 (en) 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
US10350223B2 (en) 2015-03-03 2019-07-16 Richard W. Yee Compositions and methods for treating ocular diseases
WO2016170382A1 (en) 2015-04-23 2016-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising a bradykinin 2 receptor antagonist for prevention or treatment of impaired skin wound healing
WO2017093350A1 (en) 2015-12-01 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
WO2019002168A1 (en) 2017-06-26 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME
SG11202006259SA (en) 2018-01-26 2020-08-28 Genentech Inc Il-22 fc fusion proteins and methods of use
LT3743088T (lt) 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc kompozicijos ir jų naudojimo būdai
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
JP2021514354A (ja) 2018-02-21 2021-06-10 ジェネンテック， インコーポレイテッド ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
WO2020049327A1 (en) 2018-09-05 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of hidradenitis suppurativa in patients in need thereof
WO2020064907A1 (en) 2018-09-27 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition reducing skin inflammation
CA3115038A1 (en) 2018-10-04 2020-04-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Egfr inhibitors for treating keratodermas
WO2020074549A1 (en) 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
US20220202820A1 (en) 2019-04-16 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2020239623A1 (en) 2019-05-24 2020-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ngal inhibitors for the treating chronic wound
US20220249426A1 (en) 2019-07-24 2022-08-11 Inserm (Institut National De La Santé Et De La Recherch Médicale) Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
WO2021090322A1 (en) * 2019-11-06 2021-05-14 Sol-Gel Technologies Ltd. Method of treating palmoplantar keratoderma
JP2023554180A (ja) 2020-12-10 2023-12-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ジストロフィー性表皮水疱症を治療するための物質および方法。
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2047874A6 (el) * 1969-06-10 1971-03-19 Nouvel Lucien
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
EP0137743A3 (en) * 1983-09-13 1986-10-01 Ed. Geistlich Söhne Ag Für Chemische Industrie Topically administrable pharmaceutical compositions
DE3380839D1 (en) * 1983-11-02 1989-12-21 J C R Kabushiki Kaisha Also Kn Ophthalmic preparations
CH662944A5 (it) * 1984-10-18 1987-11-13 Pier Luigi Prof Dr Luisi Procedimento per la preparazione di biocompatibili di micelle inverse di biocompatibili e loro utilizzazione.
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing

Also Published As

Publication number Publication date
JPH02112A (ja) 1990-01-05
NZ226171A (en) 1990-06-26
MX169808B (es) 1993-07-27
KR890004720A (ko) 1989-05-09
AU2223588A (en) 1989-03-23
US5427778A (en) 1995-06-27
EP0312208A1 (en) 1989-04-19
PT88541A (pt) 1989-07-31
GR880100617A (en) 1989-06-22

Similar Documents

Publication Publication Date Title
Franklin et al. Effects of topical applications of epidermal growth factor on wound healing experimental study on rabbit ears
DE69617723D1 (de) Wachsumsfaktoren enthaltende gelformulierungen
DE69010840D1 (de) Sterile chirurgische Nadel-Nähfaden-Zusammensetzung.
IT1142032B (it) Preparato che favorisce la coagulazione del sangue a base di proteine umani, nonche' procedimento per la preparazione
IT1131776B (it) Protesi anulare regolabile per chirurgia cardiaca
DK304379A (da) Ikke-absorberbar steril kirurgisk monofilamentblokcopolymersutur eller ligatur
EP0330389A3 (en) Human collagen processing and autoimplant use
NO862964L (no) Saarhelingsmidler.
DE69531254D1 (de) Arzneistofffreisetzendes chirurgisches implantat bzw. pflastermaterial
ES2064845T3 (es) Protesis implantable.
JPS55101254A (en) Surgical instrument for suturing cutaneous tissue
IT1128295B (it) Punto per suture chirurgiche
ES2027960T3 (es) Un articulo absorbente que tiene miembros de conformacion elasticos, insensibles a la humedad.
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
FR2401185B1 (fr) Copolymeres d'addition de lactide et de glycolide utilisables comme base de materiels chirurgicaux absorbables, et procede de preparation de ces copolymeres
NO152791C (no) Kopolymer for fremstilling av sterile kirurgiske suturer.
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
GR900100257A (el) Επιλογικη τοποθετηση υλικων απορροφητικου προιοντος σε σερβιεττες υγειας και παρομοια.
FI882409A7 (fi) Hitsattava mikrohuokoinen harsolaastari lääkintäkäyttöön.
ATE74605T1 (de) Tetracyclische chinazolinderivate, herstellung und verwendung.
ATA904689A (de) Chirurgische nadel
IT8603587A0 (it) Cannula per aspirazione chirurgica
SU1710069A1 (ru) Устройство дл внутриполостного электрофореза
IT8509429A0 (it) Materiali biocompatibili e emocompatibili per realizzare endoprotesi, organi e tessuti artificiali, e metodo per preparare detti materiali
SU1438731A1 (ru) Способ ринопластики